Terminal · Institutions
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Pivotal bioVenture Partners Investment Advisor LLC (CIK 1844645) reported $279.8M across 11 reported positions in its SEC 13F filing for 2026-03-31. Largest positions: PCVX ($79.8M, 28.51%), OCS ($44.7M, 15.97%), ($44.3M, 15.83%), ARQT ($31.9M, 11.42%), TRVI ($18.5M, 6.63%). Source: SEC Form 13F.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | PCVX | VAXCYTE INC | $79.8M | 28.51% | 1.4M | Hold |
| 2 | OCS | OCULIS HOLDING AG | $44.7M | 15.97% | 1.7M | Trimmed |
| 3 | EVOMMUNE INC | $44.3M | 15.83% | 1.9M | Hold | |
| 4 | ARQT | ARCUTIS BIOTHERAPEUTICS INC | $31.9M | 11.42% | 1.4M | Trimmed |
| 5 | TRVI | TREVI THERAPEUTICS INC | $18.5M | 6.63% | 1.6M | Added |
| 6 | IMNM | IMMUNOME INC | $16.0M | 5.73% | 732,512 | Hold |
| 7 | MAPLIGHT THERAPEUTICS INC | $12.4M | 4.44% | 611,447 | Hold | |
| 8 | ZBIO | ZENAS BIOPHARMA INC | $11.6M | 4.14% | 591,991 | Hold |
| 9 | BIOA | BIOAGE LABS INC | $11.4M | 4.08% | 653,374 | Hold |
| 10 | AVTX | AVALO THERAPEUTICS INC | $4.4M | 1.58% | 295,933 | New |
| 11 | RLYB | RALLYBIO CORP | $2.7M | 0.96% | 300,579 | New |
| 12 | RXRX | RECURSION PHARMACEUTICALS IN | $1.8M | 0.65% | 595,518 | Hold |
| 13 | BOLT | BOLT BIOTHERAPEUTICS INC | $172,027 | 0.06% | 42,581 | Trimmed |
| 14 | RLYB | RALLYBIO CORP | $0 | 0.00% | 0 | Exited |
Source: SEC Form 13F filings · as of 2026-03-31